Revisiting Cymer and LTC Properties

I'm not a particularly religious man, and that fact definitely helped me last week. It allowed me to literally not fear being sent to hell (as several readers wished I would be) for recommending Icos(ICOS Quote) before the Food and Drug Administration knocked the wind out the company's hopes for bringing an important drug to market this year.

But what really seemed to set a couple people off was my pointing out that the Icos position taken in InsiderInsights' Recommended List was stopped out before the gap down. Also, my reviewing of the newsletter's very good track record in what's been a very messy market was taken by some readers as my not making a proper mea culpa for the bad pick.

So to clear the air, let me just state: I'm not always right, and don't pretend to be. ...